Evidence map›Paper›PMID 38510602›Full record

ArticleBrain & spine2024

Effects of Levetiracetam and Lacosamide on survival and seizure control in IDH-wild type glioblastoma during temozolomide plus radiation adjuvant therapy.

Andrea Bianconi, Emanuele Koumantakis, Andrea Gatto, Pietro Zeppa, Ayoub Saaid, Elsa Nico, Francesco Bruno, Alessia Pellerino, Francesca Rizzo, Carola Vera Junemann and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain & spine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Andrea BianconiNeurosurgery, Department of Neuroscience, University of Turin, Turin, Italy.
Emanuele KoumantakisDepartment of Public Health and Pediatrics, University of Turin, Turin, Italy.
Andrea GattoNeurosurgery, Department of Neuroscience, University of Turin, Turin, Italy.
Pietro ZeppaNeurosurgery, Department of Neuroscience, University of Turin, Turin, Italy.
Ayoub SaaidNeurosurgery, Department of Neuroscience, University of Turin, Turin, Italy.
Elsa NicoDepartment of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Francesco BrunoNeurooncology, Department of Neuroscience, University of Turin, Turin, Italy.
Alessia PellerinoNeurooncology, Department of Neuroscience, University of Turin, Turin, Italy.
Francesca RizzoNeurosurgery, Department of Neuroscience, University of Turin, Turin, Italy.
Carola Vera JunemannNeurology, Department of Neuroscience, University of Turin, Turin, Italy.
Antonio MelcarneNeurosurgery, Department of Neuroscience, University of Turin, Turin, Italy.
Diego GarbossaNeurosurgery, Department of Neuroscience, University of Turin, Turin, Italy.
Paola DalmassoDepartment of Public Health and Pediatrics, University of Turin, Turin, Italy.
Fabio CofanoNeurosurgery, Department of Neuroscience, University of Turin, Turin, Italy.
University of Turin · ITBarrow Neurological Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: There are no clear indications for the best choice of anti-seizure medications to control brain tumor related epilepsy. In vitro studies have shown an antitumoral effect of Levetiracetam and Lacosamide on glioblastoma IDH-wild type. Research question: This study investigates whether the use of levetiracetam and/or lacosamide impacts survival rates. The secondary aim was to evaluate the efficacy of both ASMs in controlling seizures. Materials and methods: In this observational retrospective single-cohort study, patients underwent chemoradiation protocol after GBM surgery. They were grouped as follows: (1) use of levetiracetam, (2) use of lacosamide, (3) simultaneous use of levetiracetam and lacosamide, (4) no ASM usage. Survival curves were plotted using the Kaplan-Meier method coupled with a log-rank test for difference assesments. To evaluate the pharmacological efficacy of post-operative seizure control, a negative binomial regression was conducted. Results: The study included 272 patients, 174 of which underwent adjuvant chemoradiation treatment. Patients without ASM therapy had a non-significant longer median OS (compared to the other groups (log-rank = 0.37). The IRR of seizure relapse was 2.57 (p = 0.007) times higher in lacosamide users, and MGMT promoter methylation demonstrated a protective effect against postoperative seizure onset (p = 0.05), regardless of the aforementioned confounding factors. Discussion and conclusions: In patients diagnosed with GBM IDH-WT undergoing chemoradiation therapy, the use of levetiracetam or lacosamide for controlling BTRE does not seem to modify survival. Lacosamide users exhibited a higher IRR of postoperative seizures compared to levetiracetam users, and MGMT promoter methylation appears to be a protective factor.

Indexed as

Anti-Seizure medicationBrain tumor related epilepsyEpilepsyGlioblastomaLacosamideLevetiracetam

Identifiers

PMID38510602
PMCPMC10951696
OpenAlexW4389736196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.